FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.
What happened
FDA did not inspect the plant; it reviewed records the company sent after an August 25, 2025 written request for records under section 704(a)(4) of the FD&C Act, plus later correspondence. The records showed the company did not test incoming talc for asbestos or even for identity, and did not validate its suppliers' test results. FDA placed all drugs offered for import from the firm on Import Alert 66-40 on January 9, 2026.
What FDA found
The company did not test each incoming ingredient lot for identity and for purity, strength and quality against written specifications.
21 CFR 211.84(d)(1) and 21 CFR 211.84(d)(2)The company did not test its talc for asbestos, a known cancer-causing mineral that can occur naturally alongside talc and can be breathed in from the product.
21 CFR 211.84(d)(1) and (d)(2)The company relied on supplier certificates of analysis without first proving, by validating the supplier's results, that those results were reliable.
21 CFR 211.84(d)(2)The quality unit approved talc for use even though its specifications left out identity, assay, impurity and asbestos tests, and one limit was above the USP limit.
21 CFR 211.22The company's test methods and specifications for talc were not scientifically sound and fell short of the USP talc monograph, which USP-recognized drugs are generally required to meet.
21 CFR 211.160(b); section 501(b) of the FD&C Act
What FDA wants
Respond in writing within 15 working days describing what you have done to fix the violations and prevent them recurring, or explain the delay and give a completion schedule. Separately, provide talc and finished-product asbestos test results within 30 calendar days.
Who should pay attention
- brands that contract OTC drug manufacturing to this site
- companies selling talc-containing OTC drugs for the US market
- US importers and distributors of drug products made in Japan
This is a summary. Read the original letter on fda.gov.